What Is Lipoprotein(a)?

What Is Lipoprotein(a)?

Lipoprotein(a), or Lp(a), is a particle that circulates in the blood and is structurally similar to LDL cholesterol, but with an additional protein called apolipoprotein(a) attached to it. This structural difference matters: evidence suggests that Lp(a) is more likely than standard LDL to promote atherosclerosis — the buildup of plaques inside arterial walls — and may also interfere with normal blood clot breakdown.

Unlike most lipid markers, Lp(a) is almost entirely determined by genetics. Levels are set largely at birth and remain relatively stable throughout life. As a result, Lp(a) sits in a different category from cholesterol or triglycerides: it is not a consequence of diet or inactivity, but rather an inherited trait that either raises or does not raise cardiovascular risk.

Lp(a) is increasingly recognised as an important component of a thorough cardiovascular risk assessment. It is covered in more depth in our guide to the most complete longevity blood panel, which explains where Lp(a) fits alongside other key biomarkers.

Is Lipoprotein(a) a Risk Factor for Heart Disease?

Yes. Elevated Lp(a) is considered an independent risk factor for cardiovascular disease, meaning it raises risk even when other lipid markers — such as LDL, HDL, and triglycerides — appear normal. Large-scale epidemiological studies and Mendelian randomisation data both support a causal link between high Lp(a) and increased rates of heart attack, stroke, and aortic valve disease.

Who Is Most at Risk?

Elevated Lp(a) is particularly relevant for people with a personal or family history of early cardiovascular disease, especially when other obvious risk factors are absent. In these cases, undetected high Lp(a) is sometimes the explanation. However, because Lp(a) operates independently of lifestyle, it can be elevated in people who otherwise appear low-risk on a standard lipid panel.

Importantly, Lp(a) does not act in isolation. Its impact is greater when other cardiovascular risk factors — such as high ApoB, hypertension, or smoking — are also present. In contrast, when overall cardiovascular risk is already well controlled, the absolute additional risk from elevated Lp(a) may be more modest.

How Does Lp(a) Promote Arterial Disease?

Research suggests Lp(a) contributes to arterial damage through at least two mechanisms. First, it can deposit in arterial walls and promote plaque formation, in a similar way to LDL but potentially more readily. Second, apolipoprotein(a) has a structural resemblance to plasminogen — a protein involved in dissolving blood clots — and may interfere with this process, increasing the risk of clot-related events such as heart attacks.

How Is Lipoprotein(a) Measured?

Lp(a) is measured through a specific blood test that is not included in a standard lipid panel. It must be requested explicitly. The test is typically reported either in mg/dL or nmol/L, and it is worth confirming the units when interpreting results, as the two scales are not directly interchangeable.

A level above approximately 50 mg/dL (or around 125 nmol/L) is generally considered elevated, though risk increases on a continuum rather than switching sharply at a single threshold. Some guidelines suggest that levels above 30 mg/dL warrant consideration in the context of overall cardiovascular risk.

Because Lp(a) is genetically stable, it typically only needs to be measured once in adult life — unless there is a specific clinical reason to recheck. This makes it a practical one-time screening test rather than a marker to monitor regularly. Learn more in our complete guide to longevity at longevityinsights.co.uk/what-is-longevity/.

When Should You Test Lp(a)?

Testing is most useful for anyone with a family history of premature cardiovascular disease, unexplained early heart attacks in relatives, or a personal history of cardiovascular events despite apparently well-controlled conventional risk factors. It is also reasonable to test at least once as part of a comprehensive cardiovascular risk assessment, particularly when building a broader longevity blood panel.

Is Lipoprotein(a) Genetic or Modifiable?

Lp(a) is primarily genetic. Levels are determined largely by variants in the LPA gene and remain stable over a person’s lifetime. Standard lifestyle interventions — including dietary changes, aerobic exercise, and weight loss — have minimal effect on Lp(a) concentrations. This sets it apart from most other cardiovascular biomarkers and makes it more of a fixed risk signal than a modifiable target.

Can Any Treatments Lower Lp(a)?

Some pharmacological options show modest effects. Niacin (nicotinic acid) can reduce Lp(a) by around 20–30% in some individuals, though its use has declined due to side effects and uncertain cardiovascular benefit in large trials. PCSK9 inhibitors — used primarily to lower LDL — also reduce Lp(a) by roughly 20–30%, though this effect is considered secondary to their main mechanism.

More targeted approaches are in development. RNA-based therapies, including antisense oligonucleotides and small interfering RNA (siRNA) directed specifically at apolipoprotein(a), have shown substantial Lp(a) reductions in clinical trials. These treatments are not yet widely available, but they represent a meaningful advance in the management of genetically elevated Lp(a). For people with very high levels and established cardiovascular disease, specialist referral is worthwhile to stay informed about emerging options.

In the meantime, the most practical response to elevated Lp(a) is to reduce other modifiable cardiovascular risk factors as aggressively as possible — particularly ApoB, blood pressure, smoking, and inflammation. You can explore this further in our article on whether high Lp(a) increases mortality risk.

Managing High Lipoprotein(a)

Because Lp(a) cannot be meaningfully reduced through diet or exercise alone, management focuses on two areas: treating other cardiovascular risk factors more aggressively, and monitoring for relevant symptoms or disease progression.

Reducing Overall Cardiovascular Risk

For someone with elevated Lp(a), the priority is ensuring that every other controllable risk factor is well managed. This means keeping ApoB low, maintaining healthy blood pressure, avoiding smoking, managing blood glucose, and addressing chronic inflammation. Collectively, these interventions reduce the total cardiovascular risk burden — even if Lp(a) itself remains unchanged.

In practice, a clinician may set more aggressive treatment targets for other risk factors in a patient with high Lp(a) than they would in someone with the same LDL but normal Lp(a). This risk-stratification approach is one of the main practical uses of knowing your Lp(a) level.

Diet and Lifestyle: Limited but Still Relevant

Although diet and exercise do not substantially lower Lp(a), they remain important for overall cardiovascular and metabolic health. A diet rich in omega-3 fatty acids, fibre, and whole foods — combined with consistent physical activity — supports endothelial function, reduces inflammation, and improves other lipid markers. These benefits are meaningful, even if they do not directly alter Lp(a).

Pharmacological Options

For individuals with very high Lp(a) and high overall cardiovascular risk, a specialist may consider PCSK9 inhibitors or discuss access to clinical trials involving newer RNA-based therapies. These conversations are most relevant for people with both elevated Lp(a) and established cardiovascular disease, or those with a strong family history of early heart disease. That said, drug therapy for Lp(a) alone — in the absence of other risk factors — is not standard practice at this time.

For a broader look at how Lp(a) fits within a complete cardiovascular and longevity-focused assessment, see our article on whether Lp(a) can be lowered naturally.

References and Resources

Frequently Asked Questions

Conclusion

Lipoprotein(a) is a genetically determined cardiovascular risk marker that operates independently of most conventional lipid measurements. Because it cannot be meaningfully altered through lifestyle changes, its primary clinical value is as a one-time screening tool that helps clarify underlying risk — particularly in people with a family history of early heart disease or unexplained cardiovascular events.

Knowing your Lp(a) level does not change what you can do to lower it directly. However, it can inform how aggressively you and your clinician approach other modifiable risk factors. In that sense, it is a useful piece of the broader picture — not a cause for alarm on its own, but worth measuring as part of a thorough cardiovascular and longevity-focused blood assessment.